An overview and update on biosimilars
By Stephen Paul Mahinka and Kathleen M. Sanzo of Morgan, Lewis & Bockius.
The Patient Protection and Affordable Care Act of 2010 ("PPACA" or
"the Act") will significantly affect biopharma growth and investment. A
major element of this healthcare reform law is the Biologics Price
Competition and Innovation Act ("BPCIA").
The BPCIA provides...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.